abstract |
The present invention relates to the treatment of cancer, such as prostate cancer (eg, castration resistant prostate cancer (CRPC)). More specifically, the invention relates to the treatment of human patients with prostate cancer (eg, CRPC, eg, metastatic CRPC) with a combination therapy comprising a PD-1 axis binding antagonist and an antiandrogen. [Selection diagram] None |